August 16, 2026 11:48 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
After SC rebuke, BCI chief apologises to NALSAR students over enrolment freeze row | Independence Day: PM Modi’s big youth pitch— AI training, free coaching amid exam row and job concerns | ‘Shakti Ki Saptadhara’: Modi reveals 7 pillars to power India’s next leap in his I-Day speech from Red Fort | West Bengal STF arrests 3 more suspected Pakistani spies in Cooch Behar | Bengal man arrested in Bengaluru over terror links, Afghanistan travel plan | Ajit Doval breaks silence on Operation Sindoor in Discovery’s explosive new docuseries | Rahul Gandhi's 'mock hug' taunt sparks row; Centre stresses 'mutual respect' with Italy | Delhi on high alert: Bomb threat to High Court, airport and multiple locations ahead of I-Day | ‘Who are they to interfere?’: CJI Surya Kant slams Bar Council of India over NALSAR students’ enrolment row | 'Shows how low Congress has sunk': BJP slams Rahul Gandhi over Modi foreign policy jibe

GVK BIO and LifeArc celebrates 10th anniversary of partnership

| @indiablooms | May 16, 2019, at 03:37 pm

Kolkata, May 16 (IBNS): Hyderabad-based GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities,recently observed the 10th anniversary of their partnership.

The collaboration between LifeArc and GVK BIO focuses on advancing novel research ideas into potential medicines that can make a significant difference to patients.

LifeArc’s approach involves levering partnerships with academia and leading service organizations to advance discoveries into promising medicines. 

Over the past decade, LifeArc scientific teams have focused their efforts on modulating novel targets with therapeutic potential in diseases where there is patient need, with the GVK BIO team assisting in synthesizing complex molecules rapidly and cost effectively to drive iterative improvement in efficacy and safety.

Promising novel chemical entities discovered from this partnership have been either advanced by LifeArc into clinical development, or have been licensed out to leading global pharmaceutical companies, including a recently announced deal in neuroscience.

As the partnership evolved from a tactical relationship into a preferred partnership, the GVK BIO team has augmented LifeArc’s internal biology efforts, by supporting biochemical assays, carrying out drug metabolism and pharmacokinetics profiling studies, and soon, will be developing cell-based assays and running protein expression and purification studies. 

“It has been our privilege to have collaborated with LifeArc and its world class team of scientists that have delivered medicines such as Keytruda, Tysabri, and Entyvio among others," said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO.

“The longevity of this partnership, and the transformative results of the collaboration, serve as a testament to the capabilities of the GVK BIO team and its commitment to work with customers to make a difference in human life. We look forward to continuing this successful relationship with LifeArc in the coming years, he said.”

Commenting on the partnership, Melanie Lee, Chief Executive Officer, LifeArc said, “At LifeArc, we’re committed to translating scientific innovation to benefit patients. Our partnership with GVK BIO is a strong example of how shared goals and collaboration can create real value.”

 

Image Credit: GVK BIO/Facebook

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.